For Professional Clients and, in Switzerland, for Qualified Investors only. In Israel for Sophisticated Investors only.
English
  • English
  • French
en
  • en
  • fr
Filter by theme
Filter by date
Filter by boutique
Filter by theme
Filter by date
Filter by boutique
No posts matching your criteria
Clear theme
Clear all
No posts matching your criteria
Clear date
Clear all
No posts matching your criteria
Clear boutique
Clear all
For Professional Clients and, in Switzerland, for Qualified Investors only. In Israel for Sophisticated Investors only.
English
  • English
  • French
en
  • en
  • fr
© 2019. BNY Mellon Investment Management International Limited. All rights reserved.
IDEAS AND KNOWLEDGE TO INSPIRE YOUR INVESTMENTS THINKING
11 July 2019

Treating an ailing healthcare industry

Increased healthcare spending may have economic benefits but a major industry transformation is needed to curb the unsustainable cost trajectory of spending. The key is to shift away from traditional healthcare, which often focuses on reactive, prolonged and expensive treatments, towards newer developments focused on diagnostics and catching ailments before they become a problem. In Mellon’s view, advancements in newer forms of care like preventive implants and gene therapy are the “new realities of healthcare” and in our view these treatments have the ability to influence the rate of spending without ignoring efficacy and safety.

 

To ensure success, companies considered the “new realities of healthcare” need to be focused on research and development driven products, efforts to cut off runaway healthcare inflation, diagnostic and preventive techniques and the adoption of emerging technologies that could streamline workflows.

 

As the paradigm shifts towards greater emphasis on development of affordable innovations that improve health outcomes, as well as lower out-of-pocket cost and cost of care, the cure to an ailing industry does not seem far over the horizon.

 

Matthew T. Jenkin, Rick R. Rosania and Kyle M. McDonough, Mellon.

Please note the content on this website is for Investment Professionals only and should be shared responsibly. No other persons should rely on the information contained within this website.

Investment Managers are appointed by BNY Mellon Investment Management EMEA Limited (BNYMIM EMEA) or affiliated fund operating companies to undertake portfolio management activities in relation to contracts for products and services entered into by clients with BNYMIM EMEA or the BNY Mellon funds.

 

Subscribe to updates